Alzamend Neuro Dividendi e riacquisti

Criteri Dividendo verificati 0/6

Alzamend Neuro non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

-18.7%

Rendimento del riacquisto

Rendimento totale per gli azionisti	-18.7%
Rendimento futuro dei dividendi	n/a
Crescita dei dividendi	n/a
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Rapporto di remunerazione	n/a

Aggiornamenti recenti su dividendi e riacquisti

Nessun aggiornamento

Recent updates

Nuova narrativa • Aug 16

Alzamend Neuro's Novel Lithium Formulation Will Target Major Mental Health Challenges

Catalysts AL001 : a novel lithium formulation targeting Alzheimer's disease, Bipolar Disorder, Major Depressive Disorder (MDD), and PTSD. Phase II studies show promising safety/efficacy, with trials ongoing as of 2025.

Articolo di analisi • Jul 26

Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial

Alzamend Neuro (NASDAQ:ALZN) said it began dosing healthy people in a phase 2A study of oral drug AL001 treat people with dementia related to Alzheimer’s. The placebo-controlled trial (AL001-02) started in May to evaluate the safety and tolerability of AL001 under multiple-dose setting, to determine the maximum tolerated dose, the company said in an Oct. 5 press release. Based on a recommendation by the U.S. Food and Drug Administration (FDA) after its review on Alzamend's pre-investigational new drug briefing package to develop AL001 for bipolar, major depressive and post-traumatic stress disorders, the ongoing clinical trial in Alzheimer's patients was expanded, the company added. ALZN -6.52% to $1.29 premarket Oct. 5

Seeking Alpha • Sep 29

Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia

Clinical-stage biopharma Alzamend Neuro (NASDAQ:ALZN) on Thursday said it had submitted an investigational new drug (IND) application to the U.S. FDA for a phase 1/2A trial of its immunotherapy product candidate ALZN002 for the treatment of dementia of the Alzheimer's type. ALZN said the product candidate consists of dendritic cells, or activated white blood cells taken from an individual patients so that they can be engineered outside of the body to attack Alzheimer's-related amyloid-beta proteins. The purpose of the phase 1/2A trial would be to assess the safety, tolerability, and efficacy of multiple ascending doses of ALZN002 compared to placebo in 20‑30 subjects with mild to moderate dementia of the Alzheimer’s type, ALZN said in a statement. ALZN stock -1.7% to $1.16 in premarket trading. Shares of ALZN gained 6.3% on Wednesday, amidst a broader rally in drug companies that are working on Alzheimer's treatments sparked by positive data from Biogen (BIIB) and Eisai (OTCPK:ESALY).

Seeking Alpha • Jul 18

Alzamend Neuro receives positive pre-IND response from FDA for AL001

Alzamend Neuro (NASDAQ:ALZN) said on Monday it had received a written response to its meeting request relating to its Type B Pre-Investigational New Drug application from the U.S. Food and Drug Administration. The company said the FDA’s response provides a path for its planned clinical development of AL001 for the treatment of bipolar disorder, major depressive disorder and post-traumatic stress disorder. AL001 has the potential to deliver benefits of marketed lithium carbonate while avoiding current toxicities associated with lithium. Alzamend expects to file INDs for bipolar disorder, MDD and PTSD upon the completion of the current Phase IIA multiple ascending dose study.

Seeking Alpha • Dec 18

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Alzamend reported positive results from its phase 1 study using AL001 for the treatment of patients with Alzheimer's Disease. The phase 2 multiple ascending dose study using AL001 treating this patient population is expected to begin Q2 of 2022. AL002 is another shot on goal targeting Alzheimer's Disease and it is a cell therapy focused on boosting T-cell activity in the body to clear amyloid from the brain. It is estimated that the global market opportunity for Alzheimer's Disease could reach $25.5 billion by 2025.

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di ALZN siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di ALZN siano aumentati.

Rendimento dei dividendi rispetto al mercato

Alzamend Neuro Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di ALZN rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (ALZN)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.2%
Media del settore (Biotechs)	2.3%
Analista previsionale (ALZN) (fino a 3 anni)	n/a

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di ALZN rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di ALZN rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di ALZN per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché ALZN non ha segnalato alcun pagamento.

Scoprire le società che pagano dividendi forti

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/07/13 08:59
Prezzo dell'azione a fine giornata	2026/07/10 00:00
Utili	2026/01/31
Utili annuali	2025/04/30

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Alzamend Neuro, Inc. è coperta da 1 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Edward Woo	Ascendiant Capital Markets LLC

Alzamend Neuro Dividendi e riacquisti

Criteri Dividendo verificati 0/6

Informazioni chiave

Aggiornamenti recenti su dividendi e riacquisti

Recent updates

Alzamend Neuro, Inc. Reports Encouraging Pharmacodynamic Data From Phase II Clinical Trial Of AL001

Price target decreased by 33% to US$28.00

Alzamend Neuro, Inc. Reports Positive Topline Data From Phase II Clinical Trial of AL001

Alzamend Neuro, Inc. Receives Nasdaq Notice Regarding Non-Compliance with Continued Listing Rule

Alzamend Neuro Initiates Phase Ii Clinical Trial of Al001 Lithium in Brain Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

Alzamend Neuro, Inc., Annual General Meeting, Apr 17, 2026

Alzamend Neuro, Inc. Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 Lithium in Brain Study Conducted at Massachusetts General Hospital

Alzamend Neuro's Novel Lithium Formulation Will Target Major Mental Health Challenges

Alzamend Neuro, Inc. Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

Alzamend Neuro, Inc. Initiates First Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of Al001 for Treatment of Major Depressive Disorder to Take Place At Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to Take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase Ii Clinical Trial of Al001 for Treatment of Bipolar Disorder to Take Place At Massachusetts General Hospital

Alzamend Neuro, Inc., Annual General Meeting, Apr 25, 2025

Alzamend Neuro, Inc. announced that it expects to receive $5 million in funding

Alzamend Neuro, Inc. Announces Initiation Date of First Phase II Clinical Trial of AL001 to Take Place At Massachusetts General Hospital

Alzamend Neuro, Inc. Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital

Alzamend Neuro, Inc. Announces Full Data Set from Its Nonclinical Study: Comparing Brain and Plasma Lithium Carbonate in Alzheimer's Transgenic Mice

Alzamend Neuro, Inc. Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

Alzamend Neuro, Inc. has filed a Follow-on Equity Offering in the amount of $6.5 million.

Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Alzamend Neuro, Inc. announced that it expects to receive $25 million in funding

Alzamend Neuro, Inc. has completed a Follow-on Equity Offering in the amount of $1.3 million.

Alzamend Neuro, Inc., Annual General Meeting, May 13, 2024

The Nasdaq Stock Market LLC Determines Alzamend Neuro's Common Stock to be Scheduled for Delisting from The Nasdaq Capital Market and to be Suspended at the Opening of Business on April 4, 2024

Alzamend Neuro, Inc., Annual General Meeting, Apr 30, 2024

Alzamend Neuro, Inc. announced delayed 10-Q filing

Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman

Price target decreased by 67% to US$20.00

New major risk - Revenue and earnings growth

Alzamend Neuro, Inc. Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients

Alzamend Neuro Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients

Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Alzamend Neuro, Inc. Submits IND Application for A Phase IIa Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001

New major risk - Market cap size

New major risk - Share price stability

Alzamend Neuro, Inc. Submits Investigational New Drug Application for A Phase IIA Clinical Trial in Major Depressive Disorder Patients of Its Next-Generation Lithium Therapeutic Drug Candidate AL001

Price target increased by 58% to US$6.50

Alzamend Neuro, Inc Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

Alzamend Neuro Receives Non-Compliance Notice From Nasdaq

Alzamend Neuro Receives Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement

New major risk - Negative shareholders equity

Alzamend Neuro Receives Notification from Nasdaq Regarding Not Eligible for Second 180 Day Compliance Period

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

Alzamend N Neuro, Inc. Announces Positive Phase IIA Clinical Trial Results for AL001

Price target decreased by 41% to US$4.13

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$7.25

High number of new and inexperienced directors